67 results about "Neoplastic tissue" patented technology

The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed.

Methods and compositions are provided for the analysis of skin surfaces to determine the presence of neoplastic tissue. In the methods of the invention, a composition comprising a florescent probe that binds to a specific neoplasia associated marker is applied topically to the area of interest. After topical administration, the probe preferentially binds to markers associated in neoplastic lesions in situ, which binding is detected with a compact illumination unit that provides illumination at a wavelength appropriate for image acquisition. The illumination unit comprises a light source and fiber optic bundle to direct the light towards the area of examination. A detection unit is used to capture and record an image of the area of investigation. The detection unit may be a digital camera, film camera, etc. A mapping module may also be provided to catalogue the site of examination.

The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease.

The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in turn is associated with anti-apototic function and increased cell survival. The latter finding indicates that there is a positive feedback loop for CA9 expression mediated by the PI3K pathway in preneoplastic / neoplastic diseases. Disclosed herein are novel therapeutic methods for treating preneoplastic / neoplastic diseases associated with abnormal MN / CA IX expression, using EGFR pathway inhibitors. Preferably, the EGFR pathway inhibitors are tyrosine kinase inhibitors or EGFR-specific antibodies. Further disclosed are methods for patient therapy selection for EGFR pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN / CA9 gene expression in preneoplastic / neoplastic tissues.

The present invention generally relates to imaging and selective retention of phospholipid ether analogs in various neoplastic tissues. Specifically, the present invention relates to imaging and methods for selective retention of analogs, for example, NM404, in cancers such as Colorectal Cancer.

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

The present disclosure involves the use of metal-containing texaphyrins and zinc (II) reagents for the treatment of tumors, atheromas and other neoplastic tissue. The present application demonstrates increased oxidative stress, alterations in zinc homeostasis, cell cycle arrest, and apoptosis of cancer cells in the presence of texaphyrins and / or zinc. One aspect is to monitor oxidative stress and / or alterations in zinc homeostasis in target cells prior to and / or after treatment with metal-containing texaphyrins and / or zinc (II) reagents as a predictor for treatment efficacy. The present disclosure provides molecular basis for the cell cycle arrest and apoptosis on cancer cells in the presence of texaphyrins and zinc. Another aspect is to monitor different genes involved in response to treatment with texaphyrins and zinc prior to and / or after treatment as predictors for treatment efficacy.

The invention is based upon the discovery that the mitogen-activated protein kinase (MAPK) pathway can increase CA9 expression independently of HIF-1, as well as increasing CA9 expression under HIF-1-dependent pathways initiated by hypoxia or high cell density. Disclosed herein are novel therapeutic methods for treating preneoplastic / neoplastic diseases associated with abnormal MN / CA IX expression, using MAPK pathway inhibitors. Preferably, the MAPK pathway inhibitors are raf kinase inhibitors, particularly the raf kinase inhibitor Sorafenib. Further disclosed are methods for patient therapy selection for MAPK pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN / CA9 gene expression in preneoplastic / neoplastic tissues.

The invention relates to a system for measuring distribution temperature in real time in laser-induced interstitial thermotherapy and a data processing method. The system comprises a laser light source, an energy-transfer multimode fiber and a sensing fiber grating, wherein the light emitted by the laser light source is introduced into neoplastic tissues through the energy-transfer multimode fiber, a grid region of the sensing fiber grating is arranged in the neoplastic tissues, the light emitted by a broadband light source is connected to the sensing fiber grating through a fiber coupler, a reflectance spectrum is connected to an optical spectrometer through the fiber, and the optical spectrometer is connected to a computer terminal. Reflectance spectrum data is input to the computer terminal, and the distribution temperature of the treated neoplastic part is obtained through a core inversion algorithm. The system has the advantages of simple structure, easy manufacture, low cost, high precision and strong practicability, and provides a reliable plan for the real-time measurement of the tissue temperature in the course of treatment.

The present invention covers radiosensitizers containing as an active ingredient halogenated derivatives of boronated porphyrins containing multiple carborane cages having the structurewhich selectively accumulate in neoplastic tissue within the irradiation volume and thus can be used in cancer therapies including, but not limited to, boron neutron-capture therapy and photodynamic therapy. The present invention also covers methods for using these radiosensitizers in tumor imaging and cancer treatment.

This invention generally relates to a method of identifying pre-neoplastic or neoplastic tissue of a mammal by utilizing autoantibodies that detect the pre-neoplastic or neoplastic tissue. Also described herein are methods of killing pre-neoplastic or neoplastic tissue by either binding toxins to autoantibodies that detect the pre-neoplastic or neoplastic tissue or introducing toxin-conjugated molecules that can in turn recognize the autoantibodies already bound to the pre-neoplastic or neoplastic tissue.

The present invention generally relates to imaging and selective retention of phospholipid ether analogs in various neoplastic tissues. Specifically, the present invention relates to imaging and methods for selective retention of analogs, for example, NM404, in cancers such as Colorectal Cancer.

A method is disclosed for assaying the sensitivity of neoplastic tissue to therapeutic agents, and in particular, for the quantification of pro-apoptotic marker mRNA expression in cells obtained from thinly-sliced living tumor tissue in such methods. The method may comprise ascertaining a particular apoptosis marker mRNA for an individual tumor or tumor type as well as exposure of thin-sliced live cancer tissues from the individual tumor to candidate chemotherapeutic drug regimes in vitro, followed by an assessment of the level of the marker mRNA in the tissue.

The invention discloses a pulsed electric field tumour ablation parameter optimization system. The pulsed electric field tumour ablation parameter optimization system mainly comprises an image processing module, a physical parameter measuring module, a pulse electrode parameter setting module, a pulse sequence forming module, a plurality of pulse electrodes and a database, wherein the image processing model is used for obtaining biological tissue images of a user, and performing optimization processing on the biological tissue images of the user to obtain a three-dimensional structure of the biological tissue; the pulse electrode parameter setting module is used for processing received physical parameters, performing calculation to obtain pulse voltage, pulse number, pulse electrode position parameters and the depth that each pulse electrode is inserted into the biological tissue of the user, and transmitting the calculated pulse voltage, the calculated pulse number, the calculated pulse electrode position parameters and the calculated depth that each pulse electrode is inserted into the biological tissue of the user to the pulse sequence forming module; and the pulse electrodes can be used for performing pulse stimulation on the biological tissue of the user. According to the pulsed electric field tumour ablation parameter optimization system disclosed by the invention, optimal electrode arrangement and pulse parameters are arranged, so that the purposes that the tumor tissue is completely melted, and normal tissue damage and heat damage are minimum can be realized.

The disclosure concerns a medical kit arranged with componentry for fluorescein sodium (FNa)-based diagnosis and trichloroacetic acid (TCA)-based treatment of neoplastic tissue, and related methods for utilizing aspects of the medical kit.

A condition-dependent, multiple target delivery system providing multifunctional, stimuli-sensitive pharmaceutical carriers is disclosed. The delivery system simultaneously carries on its surface various active moieties. The system is multifunctional and possesses the ability to switch on and switch off certain functions when necessary, for example, under the action of local stimuli characteristic of the target pathological zone (e.g., increased temperature or lowered pH values, which are characteristic of inflamed, ischemic and neoplastic tissues).

Neoplastic tissue, viral and bacterial infections, and other physiological disorders and conditions are treated by irradiation of the host with electromagnetic radiation at a wavelength that is differentially absorbed by the offending tissue or cells. Radiation with differential absorption is also used in the sterilization of articles and packing made from synthetic polymers and for the treatment of food stuffs.

The invention discloses rebuild adenovirus that could express tumor distinguished apoptosis peptide and the method to manufacture. It rebuilds the adenovirus carrier and inducing the material that make the tumor apoptosis to achieve the aim of cure tumor.

Bacteria with tumor-targeting capability express, surface displayed, secreted and / or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.

Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of TRIM59 in the test cell sample or fluid sample as compared to the level of expression of TRIM59 in a control cell sample or fluid sample isolated from a normal subject.

A method for detecting gold or other nanoparticles conjugated to preferential locators commences by contacting tissue suspected of being neoplastic with gold nanoparticle / preferential locator conjugates for a time adequate for the conjugates to bind with the tissue. A beam of gamma photons (such as from, 99mTc) is directed at the conjugate bound tissue to remove electrons from the K-shell or L-shell, for example, of the gold nanoparticles. The removed electrons can be detected for locating neoplastic tissue or X-ray fluorescence corresponding to an electron transitioning from one shell to another shell can be detected, or by detecting resulting X-ray fluorescence corresponding to an electron transitioning from one shell to another shell, such as X-ray fluorescence arising from K-alpha emission corresponding to an electron transitioning from the L shell to the K shell. Additional X-ray fluorescing detecting molecules include Ag, I, Fe, Tc, Zn, Mn, Cr (trivalent).

A reagent kit for real-time quantitatively fluorescent RT-PCR detection of human cancino-embryonic antigen is composed of reaction liquid, M-MLV reverse transcriptase, Rnasin, PCR reaction liquid, Taq, standards and references. It can precisely and quantitatively detect the mRNA expression of CEA in specimen.

Compositions comprising motexafin gadolinium, as well as methods for using these compositions in the treatment of brain metastases, are described herein.

Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.